Arbutus Biopharma Corporation (ABUS)
After hours:
| Previous close | 2.9400 |
| Open | 2.9600 |
| Bid | 2.8700 x 500 |
| Ask | 2.9000 x 900 |
| Day's range | 2.7903 - 2.9600 |
| 52-week range | 1.6900 - 3.2900 |
| Volume | |
| Avg. volume | 1,246,773 |
| Market cap | 543.505M |
| Beta (5Y monthly) | 2.05 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.4400 |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.40 |
GlobeNewswireArbutus to Participate in Two Upcoming Investor Conferences
WARMINSTER, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in New York: The Citizens JMP Life Sciences Conference: Fi
Insider MonkeyArbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2024 Earnings Call Transcript
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2024 Earnings Call Transcript May 2, 2024 Arbutus Biopharma Corporation misses on earnings expectations. Reported EPS is $-0.10178 EPS, expectations were $-0.1. Arbutus Biopharma Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, […]
Simply Wall St.Arbutus Biopharma First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Arbutus Biopharma ( NASDAQ:ABUS ) First Quarter 2024 Results Key Financial Results Revenue: US$1.53m (down 77% from 1Q...
